Clinical Trial Update: Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing DHP107 to Taxol for metastatic or recurrent gastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• DHP107 (paclitaxel)
• Taxol (paclitaxel)

Snippet

Sponsor: Daehwa Pharmaceutical Co., Ltd. | Conditions: Stage IV Gastric Cancer | Phase 3 | Status: COMPLETED